The closing price of Hims & Hers Health Inc (NYSE: HIMS) was $15.82 for the day, down -3.00% from the previous closing price of $16.31. In other words, the price has decreased by -$0.49 from its previous closing price. On the day, 4732541 shares were traded. HIMS stock price reached its highest trading level at $16.36 during the session, while it also had its lowest trading level at $15.63.
Ratios:
Our analysis of HIMS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.34 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 69.29. For the most recent quarter (mrq), Quick Ratio is recorded 2.74 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On February 26, 2024, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $10.
On December 07, 2023, Imperial Capital started tracking the stock assigning a In-line rating and target price of $9.Imperial Capital initiated its In-line rating on December 07, 2023, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 20 ’24 when Dudum Andrew sold 50,361 shares for $16.34 per share. The transaction valued at 823,055 led to the insider holds 0 shares of the business.
Okupe Oluyemi sold 9,912 shares of HIMS for $156,816 on Mar 20 ’24. The Chief Financial Officer now owns 168,627 shares after completing the transaction at $15.82 per share. On Mar 19 ’24, another insider, Becklund Irene, who serves as the PAO of the company, sold 13,353 shares for $15.52 each. As a result, the insider received 207,239 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 3.39B and an Enterprise Value of 3.18B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.89 while its Price-to-Book (P/B) ratio in mrq is 9.82. Its current Enterprise Value per Revenue stands at 3.64 whereas that against EBITDA is -159.41.
Stock Price History:
Over the past 52 weeks, HIMS has reached a high of $17.16, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 11.55, while the 200-Day Moving Average is calculated to be 8.60.
Shares Statistics:
HIMS traded an average of 4.54M shares per day over the past three months and 5.21M shares per day over the past ten days. A total of 205.10M shares are outstanding, with a floating share count of 138.71M. Insiders hold about 35.26% of the company’s shares, while institutions hold 38.57% stake in the company. Shares short for HIMS as of Feb 29, 2024 were 12.65M with a Short Ratio of 2.78, compared to 14.42M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.90% and a Short% of Float of 7.92%.
Earnings Estimates
The firm’s stock currently is rated by 8 analysts. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.02 and a low estimate of -$0.04, while EPS last year was -$0.05. The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.14 and -$0.11 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is $0.2, with 9 analysts recommending between $0.33 and $0.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $271.65M to a low estimate of $268.9M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $190.77M, an estimated increase of 41.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $288.5M, an increase of 40.80% less than the figure of $41.80% in the same quarter last year. There is a high estimate of $291.91M for the next quarter, whereas the lowest estimate is $286.5M.
A total of 11 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $1.2B, while the lowest revenue estimate was $1.18B, resulting in an average revenue estimate of $1.19B. In the same quarter a year ago, actual revenue was $878M, up 35.70% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $1.48B in the next fiscal year. The high estimate is $1.56B and the low estimate is $1.42B. The average revenue growth estimate for next year is up 24.40% from the average revenue estimate for this year.
